CAS: 68-23-5; (8R,9S,13S,14S,17R)-17-Ethynyl-17-Hydroxy-13-Methyl-1,2,4,6,7,8,9,11,12,14,15,16-Dodecahydrocyclopenta[a]Phenanthren-3-One

上下游产品

CAS号68-22-4 炔诺酮 | CAS号1236-00-6 10β-羟基炔诺酮

📜3-Methoxy-19-Nor-17βh-Pregna-2,5(10)-Dien-20-Yn-17-Ol置于甲醇,溶剂黄146体系中,化学反应生成 异炔诺酮
参考文献:Estradiene Compounds
标题:Estradiene Compounds

专利信息

专利号:US-2008300418-A1
优先权日:2004-11-08
标 题:Synthesis of Cardiolipin Analogues and Uses Thereof
发明人：AHMAD MOGHIS U; UKKALAM MURALI K; ALI SHOUKATH M; AHMAD IMRAN
权利人:AHMAD MOGHIS U; UKKALAM MURALI K; ALI SHOUKATH M; AHMAD IMRAN
摘要:The invention provides novel synthetic methodologies for preparing cardiolipin, migrated caridiolipin (1,2-positional isomer of cardiolipin) and their analogues having varying fatty acids and/or alkyl chains with varying length and degrees of saturation/unsaturation. The method comprises (a) reacting an optically pure 1,2-O-dialkyl-sn-glycerol or 1,2-O-dialkyl-sn-glycerol with one or more phosphoramidite reagent(s), wherein a phosphite triester is produced; (b) coupling the product of (a) with glycerol, wherein a protected cardiolipin is produced; and (c) deprotecting the protected cardiolipin, such that cardiolipin is prepared. The cardiolipins and analogues thereof, prepared by the present methods, can be incorporated into liposomes, which can also include active agents such as hydrophobic or hydrophilic drugs, antisense nucleotides or diagnostic agents. Such liposomes can be used to treat diseases or can be used in diagnostic and/or analytical assays.

专利号:US-8569265-B2
优先权日:2011-05-06
标题:Deuterated analogs of (4S)-4-ethyl-4-hydroxy-11-[2- (trimethylsilyl)ethyl]-1H-pyrano[3′, 4′:6,7] indolizino [1,2-b]quinoline-3,14(4H, 12H)-dione and methods of use thereof
发明人：CHEN XINGHAI; HUANG QIULI; KOCHAT HARRY; MALAKHOV ANDREY; HAUSHEER FREDERICK H
权利人:CHEN XINGHAI; HUANG QIULI; KOCHAT HARRY; MALAKHOV ANDREY; HAUSHEER FREDERICK H; BIONUMERIK PHARMACEUTICALS INC
摘要:The present invention discloses: (i) two novel deuterated Karenitecin® analogs, pharmaceutically-acceptable salts, and/or derivatives thereof; (ii) methods of synthesis of said novel deuterated Karenitecin® analogs, pharmaceutically-acceptable salts, and/or derivatives thereof; (iii) pharmaceutically-acceptable formulations comprising said novel deuterated Karenitecin® analogs, pharmaceutically-acceptable salts, derivatives thereof; and/or, optionally, one or more additional chemotherapeutic agents; and (iv) methods of administration of said novel deuterated Karenitecin® analogs, pharmaceutically-acceptable salts, derivatives thereof; and/or, optionally, one or more additional chemotherapeutic agents, to subjects in need thereof.

专利号:WO-02051393-A2
优先权日:2000-12-22
标题:Process to increase the concentration of meiosis-activating sterols (mas) in the cholesterol synthesis and the use of potent inhibitors in the process
发明人：LINDENTHAL BERNHARD
权利人:SCHERING AG; NOVO NORDISK AS; LINDENTHAL BERNHARD
摘要:The invention relates to a process to increase the concentration of meiosis-activating sterols (MAS) in the cholesterol synthesis wherein potent inhibitors where added, the use of potent inhibitors in the cholesterol synthesis, a pharmaceutical composition comprising the potent inhibitors and the use of the inhibitors for the microbiology production of meiosis-activating sterols (MAS). In the process of the invention the Δ24-reduction or/and 4α-demethylation in the cholesterol synthesis are inhibited. As a result of this inhibition the concentration of FF-MAS and/or T-MAS as meiosis-activating sterols (MAS) are increased.

专利号:US-2006078560-A1
优先权日:2003-06-23
标 题 :Method of inducing apoptosis and inhibiting cardiolipin synthesis
发明人：JAMIL HARIS; AHMAD MOGHIS U; AHMAD IMRAN
权利人:NEOPHARM INC
摘要:The present invention provides a method for inducing apoptosis within a cell by exposing the cell to an inhibitor of cardiolipin synthesis under conditions sufficient to induce apoptosis within the cell. The method can be used to investigate or treat disorders such as cancer, obesity, and cardiovascular disorders. The invention also provides a pharmaceutical composition including an inhibitor of cardiolipin synthesis and a liposomal carrier.

专利号:US-6225298-B1
优先权日:1994-11-22
标 题 :Compositions and methods for contraception and for treatment of benign gynecological disorders
发明人：SPICER DARCY V; PIKE MALCOLM CECIL; DANIELS JOHN R
权利人:BALANCE PHARMACEUTICALS INC
摘要:Compositions and methods for use in preventing conception or treating benign gynecological disorders, wherein an effective amount of an antiprogestational agent [e.g., progesterone (progestin, progestogen, gestagen) antagonist or progesterone synthesis inhibitor] administered over a first period of time is combined with an effective amount of a progestogen for a second period of time. The antiprogestational agent is selected from single agents or mixtures thereof. The progestogen is selected from single agents or mixtures of natural or synthetic progestogens. The formulations are effective as contraceptive agents and for treatment of benign gynecological disorders including uterine fibroids, premenstrual syndrome, dysfunctional uterine bleeding, polycystic ovarian syndrome and endometriosis.

专利号:US-2008286351-A1
优先权日:2004-06-29
标 题:Pegylated Cardiolipin Analogs, Methods of Synthesis, and Uses Thereof
发明人：AHMAD MOGHIS U; UKKALAM MURALI K; ALI SHOUKATH M; AHMAD IMRAN
权利人:AHMAD MOGHIS U; UKKALAM MURALI K; ALI SHOUKATH M; AHMAD IMRAN
摘要:The invention provides synthetic methods for PEGylated cardiolipins with varying linkers. The methods can be employed to prepare PEGylated cardiolipin with different fatty acid and/or alkyl chain length with or without unsaturation. The PEGylated cardiolipin, prepared by the present methods, can be incorporated into liposomes that can also include active agents such as hydrophilic or hydrophobic drugs for the treatment of human and animal diseases. In addition, the PEGylated cardiolipin can be incorporated into liposomes that include compounds for therapeutic and diagnostic imaging. The use of such liposomes with PEGylated cardiolipin prolongs the period of liposomal circulation without disrupting the lipid bilayer.